Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4‐sclerosing cholangitis: Based on a Japanese nationwide study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.16066
Abstract: IgG4‐related sclerosing cholangitis (IgG4‐SC) is recognized as a benign steroid‐responsive disease; however, little is known about the risk of development of cancer in patients with IgG4‐SC and about how to counter this risk. read more here.
Keywords: sclerosing cholangitis; reducing relapse; risk; patients igg4 ... See more keywords